相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Kai Neben et al.
BLOOD (2012)
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
Gareth J. Morgan et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Management of treatment-emergent peripheral neuropathy in multiple myeloma
P. G. Richardson et al.
LEUKEMIA (2012)
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
Philippe Moreau et al.
BLOOD (2011)
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Mara-Victoria Mateos et al.
BLOOD (2011)
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2011)
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
Michele Cavo et al.
BLOOD (2011)
Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst et al.
BLOOD (2010)
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010
Joan Blade et al.
BLOOD (2010)
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Michel Delforge et al.
LANCET ONCOLOGY (2010)
How I treat multiple myeloma in younger patients
A. Keith Stewart et al.
BLOOD (2009)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
John D. Shaughnessy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up
Rakesh Popat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
Serum M-spike and transplant outcome in patients with multiple myeloma
David Dingli et al.
CANCER SCIENCE (2007)
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
N. C. Gutierrez et al.
LEUKEMIA (2007)
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
M. Wang et al.
HEMATOLOGY (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
J Bladé et al.
BLOOD (2005)
Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
M Cavo et al.
BLOOD (2005)
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
HE Oakervee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
E Nadal et al.
BONE MARROW TRANSPLANTATION (2004)
High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission.: Results of a non-randomized study from a single institution
J Bladé et al.
BONE MARROW TRANSPLANTATION (2000)